Os Therapies Incorporated
About
Os Therapies Incorporated — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 30 2026
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
Apr 27 2026
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
Apr 16 2026
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
Apr 13 2026
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
Apr 8 2026
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor